He previously served as President and CEO of Civitas Therapeutics and Sunovion Pharmaceuticals. He was also President and CEO of Blend Therapeutics, and President and COO at Sepracor. Earlier in ...

Key Schizophrenia Companies: Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka ...

The US regulator has approved the first nebulised long-acting muscarinic antagonist for COPD from Sunovion, offering a device that allows patients to breathe normally while taking their medicine.

Sunovion hopes the twice-daily drug will become the first nebulised long-acting muscarinic antagonist for COPD, based on phase 3 data. But the company has competition from Theravance and Mylan.